A phase 1/2 clinical trial of a new device-assisted therapy in Parkinson’s disease revealed that intracerebroventricular administration of anaerobic dopamine was safe and significantly reduced l-dopa-related complications.
- Caroline Moreau
- Pascal Odou
- David Devos